Publicaciones en colaboración con investigadores/as de Harvard University (15)

2024

  1. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

2020

  1. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

    Blood, Vol. 136, Núm. 26, pp. 3033-3040

2017

  1. The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma

    Cell Reports, Vol. 19, Núm. 1, pp. 218-224

2016

  1. Myeloma cell dynamics in response to Treatment supports a model of hierarchical differentiation and clonal evolution

    Clinical Cancer Research, Vol. 22, Núm. 16, pp. 4206-4214

  2. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by prior treatment

    Blood, Vol. 127, Núm. 6, pp. 713-721

  3. Targeting vasculogenesis to prevent progression in multiple myeloma

    Leukemia, Vol. 30, Núm. 5, pp. 1103-1115

2015

  1. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051

2009

  1. A Prolonged Therapy Improves Quality of Response, and CR Associated with Superior Outcomes, with VMP

    CLINICAL LYMPHOMA & MYELOMA

  2. Bortezomib and Melphalan as Part of VMP Are Associated with Similar Hematologic Toxicity to MP Alone

    CLINICAL LYMPHOMA & MYELOMA

  3. Erythropoiesis-Stimulating Agents: No Impact on Long-Term Outcome in MM Patients in the VISTA Trial

    CLINICAL LYMPHOMA & MYELOMA

  4. Panobinostat and Bortezomib Phase I Trial in Multiple Myeloma

    CLINICAL LYMPHOMA & MYELOMA

  5. Peripheral Neuropathy with VMP Resolves in the Majority of Patients and Shows a Rate Plateau

    CLINICAL LYMPHOMA & MYELOMA

  6. VMP Results in Fewer Bone Events and Greater ALP Increases Versus MP in the VISTA Study in Front-Line MM

    CLINICAL LYMPHOMA & MYELOMA

  7. VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study

    CLINICAL LYMPHOMA & MYELOMA

2003

  1. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group

    British Journal of Haematology, Vol. 121, Núm. 5, pp. 749-757